Semax vs Cerebrolysin
ACTH(4-10) Analog (Synthetic Peptide) · Neuropeptide Mixture (Porcine Brain Derived)
Here is how these two compounds compare, based on published research, not marketing claims.
Semax
A defined synthetic heptapeptide that upregulates BDNF and NGF; Russian-approved, administered nasally.
Cerebrolysin
A porcine brain-derived multi-peptide preparation mimicking endogenous neurotrophic factors; multiple international clinical trials across stroke and dementia.
Semax
204 studies
10 human trials
Not FDA-Approved
Cerebrolysin
658 studies
52 human trials
Not FDA-Approved
What it does
Semax
Increases brain-derived growth factors (BDNF and NGF) to support cognitive function, memory, and neuroprotection. Derived from a fragment of ACTH but engineered to have zero hormonal activity.
Cerebrolysin
Delivers brain-repair signals into tissue that the bloodstream normally cannot reach. Made of short peptide fragments derived from pig brain tissue, small enough to cross the blood-brain barrier.
How it works
Semax
Semax is a synthetic heptapeptide based on the ACTH (4-10) fragment with a Pro-Gly-Pro C-terminal extension that eliminates the adrenal hormonal effects of ACTH while preserving and enhancing the neuroprotective properties. It upregulates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), two growth factors that drive synaptic plasticity, neuronal survival, and memory consolidation. Semax also modulates dopaminergic and serotonergic neurotransmission, contributing to attention and mood regulation.
Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids produced by enzymatic breakdown of purified porcine brain proteins. The peptide fragments are small enough to cross the blood-brain barrier and mimic the activity of naturally occurring neurotrophic factors (BDNF, NGF, CNTF). Once in brain tissue, the fragments promote neuronal survival, stimulate synaptic plasticity, and support axonal growth and repair. The multi-target mechanism is the defining pharmacological feature: rather than hitting one receptor, cerebrolysin modulates several neuroprotective and neurorestorative pathways simultaneously.
How often
Semax
In Russian clinical practice, Semax is administered as a nasal spray for cognitive enhancement and stroke recovery. The compound received Russian regulatory approval. No FDA-approved product exists. Research protocols outside Russia primarily use nasal administration.
Cerebrolysin
Intravenous or intramuscular injection in clinical protocols across 40+ countries where cerebrolysin is approved. Published trials use multi-week treatment courses. Cerebrolysin is not FDA-approved in the United States; clinical availability in the U.S. does not exist through standard channels.
How strong
Semax
Russian regulatory approval for nootropic and neuroprotective indications including stroke recovery. Published human studies document BDNF elevation, cognitive improvements, and neuroprotective effects in ischemic stroke patients. The compound has both preventive (cognitive support) and therapeutic (neuroprotection after injury) research applications.
Cerebrolysin
Approved in more than 40 countries for stroke recovery, traumatic brain injury, and various forms of dementia. Large-scale clinical trials in stroke rehabilitation (CASTA, CARS) showed functional recovery benefits. The evidence base includes over 200 published studies with more than 50 human clinical trials. The strongest data is in acute ischemic stroke recovery and post-TBI rehabilitation, where multiple independent research groups have replicated findings.
Main tradeoff
Semax
Same geographic evidence concentration as Selank: Russian regulatory approval with limited Western clinical replication. The BDNF and NGF elevation mechanisms are well-characterized, but controlled Western clinical trials are absent. Available through research peptide markets; not through standard Western clinical channels. Not FDA-approved for any indication.
Cerebrolysin
Internationally approved with decades of clinical use in stroke and TBI rehabilitation across more than 40 countries. Not FDA-approved in the United States; the specific U.S. trial package the FDA requires was never completed despite international clinical evidence. The 2013 Cochrane review found the evidence insufficient to draw definitive conclusions about efficacy in dementia, though subsequent trials have added data. Injectable-only delivery limits accessibility. As a porcine-derived biological product, batch-to-batch consistency and standardization are more complex than for synthetic peptides.
Best for
Semax
- Research on BDNF and NGF upregulation as a neuroprotective and nootropic strategy
- Research on ACTH-derived peptides engineered to separate neuroprotective from hormonal effects
- Research on peptide-based cognitive enhancement and post-stroke neuroprotection
Cerebrolysin
- Research interest in neuropeptide-based neuroprotection and neuroregeneration
- Research focused on stroke recovery, traumatic brain injury rehabilitation, or dementia where international clinical trial data applies
- Research comparing multi-target neuropeptide preparations versus single-target nootropic compounds
How to choose
A good fit for Semax
- Research on defined single-molecule nootropic mechanisms (BDNF/NGF upregulation)
- Research contexts where nasal administration is preferred over injection
- Research on Russian-developed neuroprotective peptide therapeutics
A good fit for Cerebrolysin
- Research on multi-target neurotrophic approaches to neuroprotection
- Research contexts where international clinical trial data carries weight
- Research on stroke recovery, traumatic brain injury, or Alzheimer's disease
Consider both across time
Semax and Cerebrolysin represent two different approaches to neuroprotection. Semax is a defined molecule with a known mechanism (BDNF/NGF), convenient nasal delivery, and Russian regulatory backing. Cerebrolysin is a complex preparation with broader neurotrophic activity, injection delivery, and more extensive international clinical trials. The evidence structures are complementary: Semax has cleaner mechanistic characterization; Cerebrolysin has broader clinical validation across multiple neurological conditions.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- BDNF Upregulation
- NGF Upregulation
- BDNF Upregulation modulates Dopaminergic Modulation
- BDNF Upregulation drives Synaptic Plasticity Enhancement; NGF Upregulation enables Synaptic Plasticity Enhancement
- Synaptic Plasticity Enhancement connects to Cognitive Function Support; Dopaminergic Modulation connects to Cognitive Function Support
- BDNF Upregulation supports Neuroprotection; NGF Upregulation supports Neuroprotection
- Blood-Brain Barrier Crossing
- Blood-Brain Barrier Crossing enables Neurotrophic Factor Mimicry
- Neurotrophic Factor Mimicry connects to Neuronal Survival
- Neurotrophic Factor Mimicry connects to Synaptic Plasticity
- Neurotrophic Factor Mimicry connects to Axonal Growth and Repair
- Neuronal Survival connects to Cognitive and Functional Recovery; Synaptic Plasticity connects to Cognitive and Functional Recovery; Axonal Growth and Repair connects to Cognitive and Functional Recovery
Semax upregulates BDNF and NGF in the brain, driving synaptic plasticity and neuroprotection.
Cerebrolysin's peptide fragments cross the blood-brain barrier to mimic neurotrophic factors that promote neuronal survival and synaptic plasticity.
Research Evidence
Cerebrolysin has the broader clinical evidence base: multiple international randomized controlled trials across stroke recovery, traumatic brain injury, and Alzheimer's disease, conducted in multiple countries. Semax has Russian regulatory approval with published human studies in stroke recovery and cognitive enhancement, but the evidence base is more geographically concentrated. Neither is FDA-approved.
- 1.
If the research interest is neuroprotection in clinical neurological populations (stroke, dementia), Cerebrolysin has the stronger and more independently replicated evidence base.
- 2.
If the research interest is self-administered nootropic peptides, Semax is the more relevant compound. Cerebrolysin requires injection and is not suitable for self-administration.
- 3.
If the research interest is BDNF-mediated cognitive activation in a single defined molecule, Semax provides a cleaner pharmacological model.
- 4.
If the research interest is multimodal neurotrophic support across multiple growth factor pathways simultaneously, Cerebrolysin's mixture profile is more relevant.
- 5.
Neither compound has established evidence for cognitive enhancement in healthy individuals, both evidence bases are concentrated in pathological populations.
Key Limitations
- •Neither compound is FDA-approved for any cognitive indication.
- •Cerebrolysin clinical trials were conducted primarily in pathological populations (stroke, dementia, TBI) not healthy individuals seeking cognitive enhancement.
- •Semax's evidence base is concentrated in Russian-language literature with limited independent Western replication.
- •Cerebrolysin's complex mixture composition makes precise mechanistic characterization more difficult than single-molecule peptides.
- •Cerebrolysin requires intramuscular or intravenous injection, not suitable for self-administration research contexts.
- •Long-term safety and efficacy data in healthy populations is absent for both compounds.
- •Translating clinical findings from neurological disease populations to healthy cognitive enhancement is not supported by current evidence for either compound.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Semax
"Semax improved my focus and cognitive performance"
Plausible but unproven
"It helped with my brain fog after COVID"
Anecdotal only
"The nasal version works within minutes"
Plausible but unproven
Cerebrolysin
"Cerebrolysin is used in hospitals across Europe and Asia"
Supported by evidence
"Cerebrolysin improved my cognitive function after brain injury"
Plausible (clinical data exists)
Safety Comparison
Cerebrolysin has extensive safety data from international clinical trials across neurological indications. Semax has published safety data from Russian clinical studies with no significant adverse effects reported. Cerebrolysin requires injection; Semax is nasal. Both are well-tolerated in published research. Cerebrolysin's porcine origin raises theoretical concerns about immunogenicity that have not materialized as clinically significant in trial data.
Semax
Approved in Russia for cognitive impairment and stroke recovery. Favorable safety profile reported in Russian clinical data. Does not produce hormonal effects associated with full-length ACTH. Administered intranasally. Limited Western safety characterization.
Cerebrolysin
Approved in multiple countries for neurological conditions. Administered by intramuscular or intravenous injection. Favorable safety profile across a substantial body of clinical trial data. Rare hypersensitivity reactions documented. Not suitable for self-administration due to injection requirement.
What the Research Suggests
Semax and Cerebrolysin are not direct competitors, they serve different research contexts and have different practical profiles. Cerebrolysin has the stronger and more independently verified clinical evidence base, particularly for stroke and dementia populations, and is appropriately rated Human Trials contextual. Semax has a defined single-molecule mechanism and a practical administration advantage (intranasal vs injection), but a smaller and less independently replicated evidence base, rated Animal Studies. Researchers evaluating nootropic and neuroprotective peptides should treat these compounds as complementary rather than interchangeable, each is more relevant to a distinct research context.